New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
07:17 EDTHZNPHorizon Pharma acquisition to be significantly accretive, says Stifel
After Horizon Pharma announced that it would acquire Vidara Therapeutics for $660M, Stifel thinks the deal will be 10% accretive in 2014 and 10%-20% accretive beyond that. The firm believes that Horizon's deal activity is favorable overall as it increases product diversity and leverages the company's promotional activities. Stifel keeps an $18 price target and Buy rating on the shares.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
07:02 EDTHZNPHorizon announces issuance of additional notice of allowance for Pennsaid 2%
Horizon Pharma announced it received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 14/497,096, entitled "Diclofenac Topical Formulation" that covers Horizon's U.S. approved product PENNSAID 2% w/w. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the ninth U.S. patent to be listed in the Orange Book for PENNSAID 2%.
06:19 EDTHZNPPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
10:13 EDTHZNPHigh option volume stocks
Subscribe for More Information
April 17, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $38 from $31 at Piper Jaffray
Subscribe for More Information
07:11 EDTHZNPHorizon Pharma Q1 results to beat expectations by wide margin, says Stifel
Stifel believes that Horizon Pharma is benefiting from strong prescription trends, and the firm says its view was bolstered by an update on prescriptions that the company gave earlier this week. Stifel raised its price target on the stock to $40 from $30 and keeps a Buy rating on the shares.
07:03 EDTHZNPHorizon Pharma receives Notice of Allowance from USPTO for Pennsaid
Subscribe for More Information
05:51 EDTHZNPStocks with implied volatility movement; ALU HZNP
Subscribe for More Information
April 16, 2015
09:18 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
April 15, 2015
18:51 EDTHZNPHorizon Pharma 15.35M share Secondary priced at $28.25
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use